Table 2.
Azuolas, J.K. et al. [25] | El-Hage, C.M. et al. [27] | Barton, A.J. et al. [26] | |
---|---|---|---|
Study design | Prospective study | Case series | Longitudinal case series |
Number of horses | 750 1 | 4 | 5 |
Location | New South Wales and Victoria | Bellarine Peninsula, Victoria | Lockyer Valley, Queensland |
Clinical signs | |||
Lethary/exercise intolerance/poor performance | 5/5 | 2/4 | 5/5 |
Pyrexia | — | 3/4 | 2/5 |
Submandibular lymphadenopathy | — | 4/4 | — |
Oral petechiae | — | 2/4 | — |
Tachypnoea | — | — | 3/5 |
Tachycardia | 2/5 | — | — |
Muscle pain/stiffness | 4/5 | 2/4 | 5/5 |
Lameness | 4/5 | 1/4 | 2/5 |
Limb oedema | — | 3/4 | 2/5 |
Synovial effusion | 2/5 | 1/4 | 2/5 |
Inappetence/colic | 1/5 | ¼ | 2/5 |
Ataxia/incoordination | 4/5 | — | — |
Haematology/Biochemistry | |||
Hyperfibrinogenaemia | — | 3/3 | — |
Hyperglobulinaemia | — | 3/3 | — |
Neutropenia | — | — | 1/5 |
Anaemia | — | — | 1/5 |
Lymphocytosis | — | — | 1/5 |
Lymphopenia | 1/5 | ||
Creatinine kinase | — | — | 1/5 |
Aspartate aminotransferase | — | — | 1/5 |
Serology | |||
IgM titre (range) | 1:5120–1:81,920 | 1:5120–1:40,960 | 1:20,480 |
IgG titre (range) | 0–1:40,960 | 0–1:10,240 | 1:20,480 |
Viral neutralization test (range) | — | — | 1:160–1:2880 |
1 Only clinical sign from 5 horses; and serology from 3 horses were recorded.